Exhibit 99.1



                                           PRESS RELEASE - FOR IMMEDIATE RELEASE



              INYX NAMES INDEPENDENT FINANCIAL HEALTHCARE EXECUTIVE
                TO BOARD OF DIRECTORS AND HEAD OF AUDIT COMMITTEE

MIAMI -  OCTOBER  16,  2003 --  Inyx,  Inc.  (OTC BB:  IYXI),  a  developer  and
manufacturer of specialized drug delivery pharmaceutical products with expertise
in niche aerosol  technologies,  announced today the appointment of Orestes Lugo
to  Inyx's  Board  of  Directors,  as an  independent  board  member,  effective
immediately. Mr. Lugo will also head Inyx's Audit Committee.

Mr.  Lugo has more than twenty  years  experience  in  financial  management.  A
Certified Public  Accountant,  Mr. Lugo began his career with Touche Ross, where
he was a Senior  Manager in the audit  department  until 1989. He has since been
responsible  for the  financial  management  of  several  healthcare  companies,
including:  Home Intensive Care, a publicly held company in Florida  involved in
home health care;  Supreme  International,  located in Miami, a manufacturer  of
men's  clothing,  Pacificare  of Florida,  a  subsidiary  of  Pacificare  Health
Systems,  a New York Stock  Exchange-listed  provider of managed  care and other
health  insurance  products to employer groups and Medicare  beneficiaries;  and
Renex Corp., a healthcare  company that develops  dialysis clinics and completed
an initial public offering in 1997. He is currently  Chief Financial  Officer of
Renal  Carepartners,  a private health care company that also develops  dialysis
clinics. Mr. Lugo is also a board member of Momentum Consulting Corp., a private
information systems consulting firm.

Dr. Jack Kachkar,  chairman of Inyx,  said:  "We are extremely  pleased that Mr.
Lugo has joined  Inyx's  Board of  Directors.  He brings both major  independent
auditing  expertise and more than a decade of experience in corporate  financial
management  of  healthcare   companies  to  our  Board.   Mr.  Lugo's  excellent
reputation,  strong  financial  acumen  and  background  will allow our Board to
provide even greater insight and guidance for our company."

"Coupled  with  Mr.  Ron  Hodgson'   resignation  from  our  Board,  Mr.  Lugo's
appointment  increases  the  number  of  independent  Directors  on our Board of
Directors and  demonstrates  our  commitment to adding a majority of independent
directors  to ensure good  corporate  governance  and  responsible  stewardship,
thereby ensuring  transparency  for all  stakeholders and ultimately  increasing
shareholder value," he added.

Dr.  Kachkar  added:  "We are very  grateful for the  contributions  made by Mr.
Hodgson while serving as a director of our Company.  Mr. Hodgson continues to be
a major  stakeholder in Inyx and we wish him all the best  personally and in his
future business endeavors."

About Inyx
Inyx,  Inc.  is a  developer  and  manufacturer  of  specialized  drug  delivery
pharmaceutical  products.  The company's  operations  are conducted  through its
subsidiary, INyX Pharma Limited, with a focus on niche products and technologies
for  the  treatment  of  respiratory,   allergy,   dermatological   and  topical
conditions. INyX Pharma's client base comprises blue-chip ethical pharmaceutical
companies,   branded  generic  firms  and  biotechnology   groups.  INyX  Pharma
manufactures for a majority of global markets  including North America,  Europe,
Latin  America  and the Middle  East.  Inyx,  Inc.  is  headquartered  in Miami,
Florida,  with INyX  Pharma's R&D and  production  facilities  in Runcorn,  near
Manchester, England.



Safe Harbor
Statements  about the Company's future  expectations,  including future revenues
and  earnings,  and all  other  statements  in this  press  release  other  than
historical facts, are "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of
1934, and as that term is defined in the Private  Securities  Litigation  Reform
Act of 1995. The Company intends that such forward-looking statements be subject
to the safe harbors created thereby.  Since these  statements  involve risks and
uncertainties  and are  subject  to  change at any time,  the  Company's  actual
results could differ materially from expected results.


For more information, please contact:
Truc N. Nguyen, VP Media Relations              Investor Relations
Stern & Co.                                    Gary Geraci
212-888-0044                                   National Financial Communications
tnguyen@sternco.com                            781-444-6100 (x629)
- -------------------                            garyg@nationalfc.com
                                               --------------------